Correlation of 4′-[methyl-11C]-thiothymidine PET with Ki-67 immunohistochemistry separately in patients with newly diagnosed and recurrent gliomas. Issue 12 (December 2021)

• Record Type: Journal Article
• Authors: Norikane, Takashi; Mitamura, Katsuya; Yamamoto, Yuka; Hatakeyama, Tetsuhiro; Miyake, Keisuke; Toyohara, Jun; Nishiyama, Yoshihiro
• Is Part Of: Nuclear medicine communications. Volume 42:Issue 12(2021)
• Publication Date: 2021-12
• Subjects: 4 -- -[methyl-11C]-thiothymidine -- glioma -- PET; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000001463
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : Objective: 4′-[methyl- 11 C]-thiothymidine (4DST) uptake on PET was correlated with proliferative activity separately in patients with newly diagnosed and recurrent gliomas. Methods: A total of 29 patients, 18 with newly diagnosed gliomas and 11 with recurrent gliomas who underwent 4DST PET/computed tomography (CT) were available for a retrospective analysis of prospectively collected data. The maximum standardized uptake value (SUVmax) of tumor (T) and the mean SUV of normal contralateral hemisphere (N) were calculated, and the tumor-to-normal (T/N) ratio was determined. Proliferative tumor volume (PTV) and total lesion proliferation (TLP) were also calculated. Proliferative activity as indicated by the Ki-67 index was estimated in tissue specimens. Immunohistochemical findings were correlated with 4DST PET parameters. Results: All gliomas but three newly diagnosed gliomas had 4DST uptake on PET. No significant differences in SUVmax, T/N ratio, PTV, or TLP were observed between the newly diagnosed and recurrent gliomas. In the former, correlations between SUVmax ( r = 0.57, P = 0.02), T/N ratio ( r = 0.51, P = 0.03), PTV ( r = 0.74, P < 0.001), and TLP ( r = 0.76, P < 0.001) and the Ki-67 index were found. In the latter, the results did not seem to suggest any correlations between any of the PET parameters and Ki-67 index. Conclusion: Although preliminary, these results suggest that 4DST PET may be useful for the noninvasive evaluation of proliferation in patients with newly diagnosed gliomas. These data in a small recurrent patient population do not support a clear-cut correlation between 4DST uptake and proliferation.